Biocracked
Approach: conceptual metaphor. Palette: D, bold color field.

A saturated mustard-yellow backdrop fills the frame. Three clear glass beakers stand in a row on a matte surface, shot at eye level with a slightly low camera angle and a shallow depth of field. Each holds a different level of clear liquid (low, medium, high). The first two look identical and empty-seeming, while the third has a thin thread of vivid green liquid (#00e676) curling through it, a small accent against the yellow. Soft, large-source studio light comes from the left and casts crisp, short shadows onto the surface. Gentle highlights run along the glass rims, and tiny bubbles cling to the inner walls. The mood is quiet, curious and analytical, suggesting that a result shows up only for some. No text, labels or markings are visible.
Longevity

ਗਲਾਈਨੈਕ ਟਰਾਇਲ ਜਿਸ ਨੇ ਗਲੁਟਾਥਾਇਓਨ ਨਹੀਂ ਵਧਾਇਆ, ਸਿਵਾਏ ਇਕ ਸਮੂਹ ਦੇ

Helix Ward · · 4 min read

A 114-person randomized trial of GlyNAC, the glycine and N-acetylcysteine combination marketed as an anti‑aging glutathione booster, missed its primary endpoint. Glutathione did not go up in the group as a whole. It did rise in one subgroup, defined after the fact, and that detail matters more than the headline result.

Why GlyNAC got so much attention

Glutathione is a tripeptide the body builds from glycine, cysteine and glutamate. It neutralizes reactive oxygen species and helps limit tissue damage. Glycine and cysteine are non‑essential amino acids, but the idea is that demand for glutathione rises with age, and that supplying more of its raw materials could restore it.

GlyNAC pairs glycine with N‑acetylcysteine (NAC), a more stable precursor of cysteine. Earlier, smaller studies, notably from a research group at Baylor College of Medicine, generated much of the enthusiasm around the combination as a way to counter age‑related decline. This 2022 paper in Frontiers in Aging is a different kind of test: a larger, placebo‑controlled, dose‑ranging trial run by Nestlé researchers.

What the trial actually did

  • Participants: 114 healthy older adults, mean age 65. A reference group of 20 younger adults (mean age 31.7) provided a comparison at baseline.
  • Doses: 2.4 g, 4.8 g or 7.2 g per day, versus placebo.
  • Ratio: glycine and NAC at 1:1.
  • Duration: two weeks.
  • Primary endpoint: total glutathione (GSH‑T) in blood.
  • Registration: ClinicalTrials.gov NCT05041179.

The older adults really did look more oxidatively stressed

Even though these volunteers were healthy, they differed from the younger reference group at baseline, with all differences at p < 0.0001 except the ratio:

  • Malondialdehyde (MDA), a lipid‑damage marker: 0.158 vs. 0.136 µmol/L
  • Total cysteine: 314.8 vs. 276 µM
  • Oxidized glutathione (GSSG): 174.5 vs. 132.3 µmol/L
  • Ratio of reduced to oxidized glutathione (GSH‑F:GSSG): 11.78 vs. 15.26 (p = 0.0018)

This supports the premise that older adults carry a heavier oxidative burden. It does not show that a supplement fixes it.

The null primary result

GlyNAC was safe and well tolerated, but it did not move the main numbers. At the end of the study:

  • GSH‑F:GSSG: 12.49 in placebo vs. 12.65 at 7.2 g (p = 0.739)
  • Total glutathione: 903.5 mg/L in placebo vs. 959.6 mg/L at 7.2 g (p = 0.278)

The top dose produced a small numerical bump in total glutathione, but it was not statistically distinguishable from placebo. Across healthy older adults as a whole, two weeks of GlyNAC did not measurably raise glutathione.

The one group that did respond

The authors then ran post‑hoc analyses. They isolated people with high oxidative stress (MDA above the median) and low baseline glutathione (GSH‑T below the median). In that subset, those taking the medium and high doses (4.8 g and 7.2 g, pooled) had higher glutathione at the end of the study: 905.4 mg/L vs. 819.7 mg/L for placebo (p = 0.016).

The finding is interesting, but it needs caution:

  • It was post‑hoc. The subgroup was defined after the primary result came back null, so it is hypothesis‑generating, not confirmatory.
  • Median splits are arbitrary. Slicing a cohort on two variables creates many chances for a chance finding.
  • Doses were pooled. The responder result combines the 4.8 g and 7.2 g groups, which says little about a precise dose‑response relationship.
  • The subgroups are small. Splitting 114 people across several arms and two median cutoffs leaves few people per cell.

The pattern is biologically plausible, though. If the body is short of glutathione and under oxidative pressure, extra precursors might matter more than in someone whose levels are already adequate.

Limits worth keeping in view

  • Two weeks is short. The trial measured blood biomarkers over a brief window. It says nothing about longer‑term effects, and it measured no clinical outcomes such as strength, cognition or disease risk.
  • Healthy volunteers only. The results may not apply to people with chronic disease or frailty, who may be the ones with the highest glutathione demand.
  • Biomarkers are not outcomes. Higher blood glutathione is a surrogate marker, not proof of better health.
  • Industry sponsorship. The authors are largely Nestlé employees, and Nestlé Health Science holds patents and markets products involving glycine and NAC. The trial was conducted with the contract research organization Profil, which received Nestlé funding. That does not invalidate the work, and the null primary result was reported plainly, but readers should know.

Practical takeaways

Who might benefit? If anyone does, the data point to people with high oxidative stress and low glutathione, not healthy older adults in general. This is a signal from a post‑hoc analysis, not an established indication.

Doses tested: 2.4, 4.8 and 7.2 g/day total at a 1:1 glycine‑to‑NAC ratio. Only the 4.8 g and 7.2 g doses showed an effect in the responder subgroup. The abstract does not describe dosing schedules or timing relative to meals, so no timing recommendation can be drawn from it.

Testing: The responder definition depended on measuring MDA and glutathione at baseline. Those are research‑style assays and not typical routine labs, which makes it hard for an individual to know which group they fall into. Taking the supplement blindly is a gamble on the average result, and the average result was null.

Safety: GlyNAC was well tolerated over the two weeks studied. That says little about long‑term use. Anyone with a medical condition or on medication should check with a clinician first.

Bottom line

This trial does not debunk GlyNAC, and it does not validate the hype. It suggests that glutathione is not simply low in everyone who is older, and that precursor supplementation may only help people who are actually depleted. A larger, longer trial that prespecifies the high‑oxidative‑stress, low‑glutathione group, ideally with independent funding, would turn this hint into an answer.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

HW

Written by

Helix Ward

Helix Ward writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

A softly lit, minimalist still life on a pale oatmeal-colored linen surface, photographed from a slightly elevated three-quarter angle in a wide landscape frame. On the left, two small matte ceramic bowls in warm off-white and sage green hold fine white crystalline powder, one a little fuller than the other, with a few scattered grains catching the light. A slim brushed-brass measuring spoon rests beside them. In the center, a clear glass of water with a faint ripple, next to a small amber glass supplement bottle with a blank cream label and a few white capsules spilled onto the linen.

On the right, a sprig of fresh rosemary and a halved lemon add organic texture and a muted citrus yellow. A neat stack of two thick cream notebooks sits behind them, topped with a pair of thin round tortoiseshell reading glasses and a sharpened pencil. An open notebook page shows hand-drawn minimalist line charts, a simple upward curve and two small bar graphs, in soft graphite with no legible text.

Behind the arrangement, a blurred sunlit window casts long, gentle diagonal shadows across the surface, with sheer curtains diffusing the morning light. The background is a creamy neutral wall with a hint of a potted olive plant at the edge. The palette is warm and calm: ivory, sage, soft terracotta, pale gold, and touches of amber. Shallow depth of field keeps the bowls and bottle sharp while the background melts into soft bokeh. The mood is clean, editorial, and thoughtful, like a modern health and wellness magazine cover, with generous negative space in the upper left for a headline overlay. Subtle film grain, natural color grading, no people, no text, and no futuristic elements.
supplements

GlyNAC ਟਰਾਇਲ: ਗਲਾਈਸੀਨ + NAC ਨੇ 16 ਹਫ਼ਤਿਆਂ ਵਿੱਚ ਬਜ਼ੁਰਗਾਂ ਦੇ ਕਈ ਉਮਰ‑ਸੰਕੇਤਕ ਪੈਰਾਮੀਟਰ ਠੀਕ ਕੀਤੇ, ਪਰ ਅਧਿਐਨ ਛੋਟਾ ਹੈ

BY DR. SYNAPSE ·

ਬੈਲਰ ਕਾਲਜ ਆਫ ਮੈਡੀਸਿਨ ਦੇ ਇੱਕ ਛੋਟੇ ਰੈਂਡਮਾਈਜ਼ਡ ਟਰਾਇਲ ਵਿੱਚ 16 ਹਫ਼ਤਿਆਂ ਤੱਕ GlyNAC (ਗਲਾਈਸੀਨ + N‑acetylcysteine) ਲੈਣ ਨਾਲ ਬਜ਼ੁਰਗਾਂ ਵਿੱਚ ਗਲੂਟਾਥਿਓਨ ਦੀ ਕਮੀ, ਓਕਸਿਡੇਟਿਵ ਸਟ੍ਰੈਸ, ਮਾਈਟੋਕੋਂਡਰੀ ਦੀ ਖ਼ਰਾਬੀ ਅਤੇ ਸੁੱਜਣ ਵਿੱਚ ਸੁਧਾਰ ਆਇਆ। ਹਿਸਸਿਆਂ ਨੇ ਸ਼ਾਰਰੀਕ ਕਾਰਗੁਜ਼ਾਰੀ ਅਤੇ ਕਈ ਉਮਰ‑ਸੰਕੇਤਕ ਚਿੰਨ੍ਹਾਂ ‘ਚ ਵੀ ਤਰੱਕੀ ਦਿਖਾਈ, ਜਦਕਿ ਪਲੇਸੀਬੋ ਨੇ ਕੋਈ ਬਦਲਾਅ ਨਹੀਂ ਕੀਤਾ। ਡੋਜ਼ ਲਗਭਗ 100 ਮਿ.ਗ੍ਰਾ./ਕਿ.ਗ੍ਰਾ. ਹਰ ਐਮੀਨੋ ਐਸਿਡ ਦੀ ਸੀ, ਜੋ ਆਮ ਸਪਲਿਮੈਂਟਾਂ ਦੀ ਖੁਰਾਕ ਤੋਂ ਕਾਫੀ ਉੱਚੀ ਹੈ। ਸਿਰਫ਼ 12‑12 ਵਿਅਕਤੀ ਪ੍ਰਤੀ ਗਰੁੱਪ ਅਤੇ ਬਾਇਓਮਾਰਕਰ‑ਕੇਂਦਰਤ ਨਤੀਜਿਆਂ ਨਾਲ ਇਹ ਅਧਿਐਨ ਵਾਅਦੇਦਾਰ ਪਰ ਅੰਤਿਮ ਨਹੀਂ ਹੈ।

Approach: macro science. Palette: bold color field, a saturated teal backdrop.

Extreme close-up microscopy-style photograph of a thin slice of rat heart muscle on a glass slide, stained in rich magenta-pink with fine, wavy parallel muscle fibers. In one half of the frame the fibers are neat and orderly. In the other half, thick pale-blue-grey strands of fibrous scar tissue cut across them in a ragged band. The slide sits on a saturated teal surface and is shot from slightly above at a shallow angle, so the glass edge catches a crisp highlight. Soft, even studio light with a shallow depth of field blurs the slide's far corner. A single tiny electric green marker dot sits on the slide's edge. The mood is precise, investigative and slightly tense, with a vivid, graphic contrast between the teal and the magenta tissue. No text or labels.
supplements

GlyNAC ਨੇ ਡਾਇਬੈਟਿਕ ਚੂਹਿਆਂ ਦੇ ਦਿਲਾਂ ਦੀ ਸਕੈਰਿੰਗ ਨੂੰ ਰੋਕਿਆ—ਪਰ ਇਕ ਗੱਲ ਧਿਆਨ ਵਿੱਚ ਰੱਖੋ

BY NOVA CHEN ·

ਇੱਕ ਨਵੀਂ ਚੂਹਾ ਅਧਿਐਨ ਵਿੱਚ ਪਤਾ ਲਗਿਆ ਕਿ ਗਲਾਈਸਿਨ + NAC (GlyNAC) ਜੋੜਾ ਡਾਇਬੈਟਿਕ ਚੂਹਿਆਂ ਵਿੱਚ ਦਿਲ ਦੀ ਸੰਰਚਨਾ ਨੂੰ ਸਭ ਤੋਂ ਵਧੀਆ ਢੰਗ ਨਾਲ ਸੰਭਾਲਦਾ ਹੈ ਅਤੇ ਮਹੱਤਵਪੂਰਨ ਤਣਾਅ ਸੰਕੇਤਾਂ ਨੂੰ ਘਟਾਉਂਦਾ ਹੈ। ਪਰ ਇਹ ਜੋੜਾ ਹਰ ਪੱਖ ‘ਚ ਜਿੱਤ ਨਹੀਂ ਸਕਿਆ, ਕਿਉਂਕਿ NAC ਇਕੱਲਾ ਕੁਝ ਆਕਸੀਡੇਟਿਵ‑ਸਟ੍ਰੈਸ ਮਾਰਕਰਾਂ ‘ਤੇ ਵਧੀਆ ਪ੍ਰਭਾਵ ਦਿਖਾਉਂਦਾ ਸੀ। ਅਧਿਐਨ 34 ਚੂਹਿਆਂ ‘ਤੇ ਸਟਰੇਪਟੋਜ਼ੋਟੋਸਿਨ-ਪੈਦਾ ਕੀਤੀ ਡਾਇਬੀਟੀਜ਼ ਮਾਡਲ ‘ਤੇ ਕੀਤਾ ਗਿਆ, ਜੋ ਮਨੁੱਖੀ ਡਾਟਾ ਨਹੀਂ ਹੈ। ਲੇਖਕਾਂ ਨੇ ਕੀ ਖੋਜਿਆ, ਕਿਉਂ ਚੂਹਿਆਂ ਦੀ mg/kg ਡੋਜ਼ ਮਨੁੱਖਾਂ ‘ਤੇ ਲਾਗੂ ਨਹੀਂ ਹੁੰਦੀ, ਅਤੇ NAC ਨਾਲ ਸੰਬੰਧਤ ਚੇਤਾਵਨੀਆਂ, ਇਹ ਸਭ ਅਗਲੇ ਹਿੱਸੇ ਵਿੱਚ ਚਰਚਿਤ ਹਨ।

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 ਨੇ ਉਮਰਦਾਰ ਚੂਹਿਆਂ ਵਿੱਚ ‘ਪੁਰਾਣੀਆਂ’ ਪਲੇਟਲੇਟਾਂ ਨੂੰ ਸ਼ਾਂਤ ਕੀਤਾ — ਇੱਥੇ ਹੈ ਗੱਲ

BY NOVA CHEN ·

ਨਵੀਂ *Aging Cell* ਅਧਿਐਨ ਦਿਖਾਉਂਦੀ ਹੈ ਕਿ CoQ10 ਨੇ ਚੂਹਿਆਂ ਵਿੱਚ ਉਮਰਦਾਰ ਮੇਗਾਕੈਰਿਕੋਇਟਸ (ਹੱਡੀ ਦੇ ਗੁੱਧੀ ਦੀਆਂ ਉਹ ਕੋਸ਼ਿਕਾਵਾਂ ਜੋ ਪਲੇਟਲੇਟ ਬਣਾਉਂਦੀਆਂ ਹਨ) ਦੀ ਕਾਰਗੁਜ਼ਾਰੀ ਵਿੱਚ ਸੁਧਾਰ ਕੀਤਾ। ਇਲਾਜ ਕੀਤੇ جانਵਰਾਂ ਵਿੱਚ ਪਲੇਟਲੇਟ ਇਕੱਠੇ ਹੋਣ ਅਤੇ ਸਰਗਰਮ ਹੋਣ ਦੀ ਦਰ ਘੱਟ ਰਹੀ, ਪਰ ਪਲੇਟਲੇਟ ਗਿਣਤੀ ਵਿੱਚ ਕੋਈ ਤਬਦੀਲੀ ਨਹੀਂ ਆਈ। ਇਹ ਪ੍ਰਭਾਵ ਹਿੱਸੇਦਾਰ COPS3 ਅਤੇ ਆਟੋਫੈਗੀ ਦੇ ਰਾਹੀਂ ਲੱਗਦਾ ਹੈ, ਪਰ ਹੁਣ ਤੱਕ ਮਨੁੱਖੀ ਡਾਟਾ ਜਾਂ ਥੱਕੀ‑ਰੋਕਥਾਮ ਦੀ ਕੋਈ ਸਬੂਤ ਨਹੀਂ।

Approach: Lab in action. Palette: B, warm.

Close, slightly high three-quarter angle on an isolated rat heart suspended in a Langendorff perfusion rig, the small dark-red heart held by its aorta on a glass cannula inside a warm-jacketed glass chamber. Clear perfusion fluid drips from the heart and beads on the glass. A gloved hand in the soft-focus foreground adjusts a stopcock. Amber, honey-colored light from a low side lamp rakes across the curved glass, producing copper highlights and warm brown shadows. Behind it, a blurred bench holds tubing and a small pressure transducer. A thin electric green (#00e676) indicator light glows on the instrument at the edge of the frame. Mood: quiet, focused, cautiously hopeful, with real laboratory texture and shallow depth of field. No text or labels.
longevity

ਦੋ ਪ੍ਰਸਿੱਧ ਸਪਲੀਮੈਂਟਾਂ ਨੇ ਵਧੇਰੇ ਉਮਰ ਵਾਲੇ ਚੂਹਿਆਂ ਦੇ ਦਿਲਾਂ ਨੂੰ ਬਚਾਇਆ – ਹਕੀਕਤ ਕੀ ਹੈ

BY DR. SYNAPSE ·

ਇੱਕ ਨਵੀਂ ਚੂਹਾ ਅਧਿਐਨ ਨੇ ਦਰਸਾਇਆ ਕਿ NMN ਨੂੰ ਮੇਲਾਟੋਨਿਨ ਨਾਲ ਜੋੜਨ ਨਾਲ ਬੁੱਢੇ ਦਿਲਾਂ ਨੂੰ ਹਾਰਟ‑ਅਟੈਕ‑ਜਿਹੀ ਚੋਟ ਤੋਂ ਇਕੱਲੀ ਦਵਾਈ ਨਾਲੋਂ ਵਧੀਆ ਠੀਕ ਕੀਤਾ ਜਾ ਸਕਦਾ ਹੈ। ਇਲਾਜ ਕੀਤੇ ਦਿਲਾਂ ਵਿੱਚ ਕੋਰੋਨਰੀ ਫ਼ਲੋ ਅਤੇ ਦਬਾਅ ਦੀ ਪੁਨਰਸਥਾਪਨਾ ਸੁਧਰੀ, ਕ੍ਰੀਐਟਿਨ ਕੀਨੇਜ਼ ਅਤੇ ਸੋਜ ਦੇ ਨਿਸ਼ਾਨਿਆਂ ਵਿੱਚ ਕਮੀ ਦੇਖੀ ਗਈ। ਪਰ ਇਹ ਨਤੀਜੇ ਚੂਹਿਆਂ ਦੇ ਦਿਲਾਂ ‘ਤੇ ex‑vivo ਤਰੀਕੇ ਨਾਲ ਲਾਗੂ ਕੀਤੇ ਗਏ ਹਨ, ਜਿਸ ਕਰਕੇ ਮਨੁੱਖੀ ਲਾਭ ਬਾਰੇ ਕੋਈ ਦਾਅਵਾ ਨਹੀਂ ਕੀਤਾ ਜਾ ਸਕਦਾ। ਇੱਥੇ ਪਤਾ ਲਗਦਾ ਹੈ ਕਿ ਖੋਜਕਾਰਾਂ ਨੇ ਕੀ ਕੀਤਾ, ਕੀ ਲੱਭਿਆ ਅਤੇ ਕਿਉਂ ਇਹ ਸਿਰਫ਼ ਪਹਿਲਾ ਕਦਮ ਹੈ।

This page is available in